Oruka Therapeutics, Inc. Severance Costs
Oruka Therapeutics, Inc. (ORKA) reported Severance Costs of $159.00 thousand for the 12-month period ending 2023-12-31, per its 10-Q filed 2024-08-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2024-08-01
- Oruka Therapeutics, Inc. severance costs for the quarter ending 2023-12-31 was $0.00.
- Oruka Therapeutics, Inc. severance costs for the quarter ending 2023-09-30 was $0.00.
- Oruka Therapeutics, Inc. severance costs for the quarter ending 2023-06-30 was $0.00.
- Oruka Therapeutics, Inc. severance costs for the quarter ending 2023-03-31 was $159.00K.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2024-08-01 | $0.00 derived: sum of 2 quarters · filed 2024-08-01 | $0.00 derived: sum of 3 quarters · filed 2024-08-01 | $159.00K 10-Q · filed 2024-08-01 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-18 | $0.00 derived: sum of 2 quarters · filed 2023-10-18 | $159.00K 10-Q · filed 2023-10-18 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-21 | $159.00K 10-Q · filed 2023-07-21 | ||
| 2023-03-31 | $159.00K 10-Q · filed 2023-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |